Ann Oncol 2019 Oct 1
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.
Related Questions
New answer by Medical Oncologist at University of Michigan Medical School (May 24, 2021)
I do not routinely use growth factor support nor trilaciclib with chemotherapy or chemo-immunotherapy for people with ES-SCLC. My starting doses of chemo are usually carboplat...